moxifloxacin has been researched along with besifloxacin in 22 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (besifloxacin) | Trials (besifloxacin) | Recent Studies (post-2010) (besifloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 74 | 15 | 44 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Cavet, ME; Ward, KW; Zhang, JZ | 1 |
| Brunner, LS; Comstock, TL; Haas, W; McDonald, MB; Morris, TW; Paterno, MR; Protzko, EE; Usner, DW | 1 |
| Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A | 2 |
| Bertino, JS; Zhang, JZ | 1 |
| Carter, NJ; Scott, LJ | 1 |
| Comstock, TL; Paterno, MR; Pichichero, ME; Usner, DW | 1 |
| Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Kim, A; Pratzer, KA; Stark, WJ; Yoshida, J | 1 |
| Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Proksch, JW; Ward, KW | 1 |
| Balzli, CL; Caballero, AR; O'Callaghan, RJ; Tang, A; Weeks, AC | 1 |
| Morris, TW; Scassellati Sforzolini, B; Sheets, JW | 1 |
| Haas, W; Hesje, CK; Morris, TW; Pillar, CM; Sanfilippo, CM | 1 |
| Comstock, TL; Donnenfeld, ED; Proksch, JW | 1 |
| Bertino, JS; Jones, RN; Segreti, J | 1 |
| Newsom, TH; Nielsen, S; Parekh, JG | 1 |
| Chung, JL; Kim, BY; Lee, JH; Lim, EH; Mah, FS; Seo, KY; Song, SW | 1 |
| Clinch, TE; Majmudar, PA | 1 |
| Carrijo-Carvalho, LC; Carvalho, FR; de Freitas, D; E Silva, FB; Teixeira, A | 1 |
2 review(s) available for moxifloxacin and besifloxacin
| Article | Year |
|---|---|
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Clinical Trials as Topic; Conjunctivitis, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2009 |
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Quinolines | 2012 |
3 trial(s) available for moxifloxacin and besifloxacin
| Article | Year |
|---|---|
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azepines; Child; Child, Preschool; Conjunctiva; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Infant; Male; Microscopy, Acoustic; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Treatment Outcome; Visual Acuity | 2009 |
Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Cataract Extraction; Chromatography, High Pressure Liquid; Cornea; Double-Blind Method; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2010 |
Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Chromatography, Liquid; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Quinolines; Tandem Mass Spectrometry | 2011 |
17 other study(ies) available for moxifloxacin and besifloxacin
| Article | Year |
|---|---|
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Azepines; Biological Transport; Cell Nucleus; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Endophthalmitis; Enzyme Activation; Epithelium, Corneal; Female; Fluoroquinolones; Humans; Interleukin-1beta; Mitogen-Activated Protein Kinases; Moxifloxacin; NF-kappa B; Quinolines; Rabbits | 2008 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2009 |
Besifloxacin ophthalmic suspension 0.6%.
Topics: Administration, Topical; Anti-Bacterial Agents; Antifungal Agents; Aza Compounds; Azepines; Colony Count, Microbial; Conjunctivitis, Bacterial; DNA Gyrase; DNA Topoisomerase IV; Double-Blind Method; Drug Administration Schedule; Eye; Fluoroquinolones; Humans; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suspensions | 2010 |
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Topics: Administration, Topical; Adolescent; Anti-Bacterial Agents; Aza Compounds; Azepines; Child; Child, Preschool; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Humans; Infant; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Treatment Outcome | 2010 |
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Ophthalmic Solutions; Penicillin Resistance; Pneumococcal Infections; Quinolines; Rabbits; Severity of Illness Index; Streptococcus pneumoniae; Time Factors | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Disease Susceptibility; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Sequence Analysis, DNA | 2011 |
Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Conjunctivitis, Bacterial; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus Infections; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Streptococcal Infections | 2010 |
Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.
Topics: Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Colony-Forming Units Assay; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2010 |
Relevance of aqueous humor concentrations of fluoroquinolones.
Topics: Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Endophthalmitis; Fluoroquinolones; Half-Life; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2011 |
In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Topics: Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Benzalkonium Compounds; Drug Interactions; Fluoroquinolones; Gatifloxacin; Microbial Viability; Moxifloxacin; Quinolines; Time Factors | 2011 |
Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azepines; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Retrospective Studies | 2012 |
Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Aza Compounds; Azepines; Biological Availability; Chromatography, High Pressure Liquid; Conjunctiva; Cornea; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Tissue Distribution; Vitreous Body | 2013 |
Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Topics: Adult; Aged; Antibiotic Prophylaxis; Azepines; Epidemiological Monitoring; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Prospective Studies; Suspensions; Topoisomerase II Inhibitors; Treatment Outcome; Visual Acuity | 2014 |
Toxicity of Intracameral Injection of Fourth-Generation Fluoroquinolones on the Corneal Endothelium.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Azepines; Cell Survival; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Human Umbilical Vein Endothelial Cells; Humans; Injections, Intraocular; Male; Moxifloxacin; Ophthalmic Solutions; Rabbits; Topoisomerase II Inhibitors | 2016 |